Loading
institutionsInstitution
Hadassah Medical Center
Jerusalem's university hospital and Sharett Institute of Oncology, known for in-house CAR-T, BRCA founder mutation research and melanoma immunotherapy.
Also called: Hadassah University HospitalSharett Institute of OncologyHadassah Ein Kerem
Overview
Hadassah Medical Center's Ein Kerem and Mount Scopus campuses house the Sharett Institute of Oncology and the Hebrew University's medical faculty. Polina Stepensky's bone marrow transplantation and immunotherapy department manufactures its own CD19 and BCMA CAR-T products, making Hadassah one of the first hospitals worldwide to deliver academic point-of-care CAR-T at scale; Michal Lotem's melanoma unit has long run tumour vaccine and immunotherapy trials, Tamar Peretz's oncogenetics group characterised BRCA founder mutations in Ashkenazi Jewish populations, and Aron Popovtzer leads head and neck oncology. The centre provides radiotherapy, gamma knife, paediatric haemato-oncology and a phase 1 unit for Jerusalem and the surrounding region.
Location
Jerusalem, IL
Type
hospital · Hebrew University of Jerusalem
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#72 · 44 points (0 Newsweek + 0 NCI + 44 from 22 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.
Matched to Hadassah Medical Center, including child institutions. 358 works · 2,931 citations · 70% open access · 14% clinical trials · 2% reviews.
Oncology works per year
622022
882023
832024
722025
532026
Most works
- Steven D. Wexner33 works
- Rachel Gefen32 works
- Sameh Hany Emile32 works
- Zoe Garoufalia32 works
- Nir Horesh31 works
- Sigal Grisariu20 works
- Polina Stepensky19 works
- Batia Ronit Avni19 works
- Diana Averbuch18 works
- Shani Paluch–Shimon16 works
Most cited
- Point-of-care CAR-T
- Oncogenetics and BRCA
- Melanoma immunotherapy
- Head and neck oncology
- Paediatric haemato-oncology
Polina Stepensky
Director, Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center
Haematopoietic stem cell transplantationAcademic CAR-T manufactureMultiple myeloma
Runs a hospital department that makes its own CAR-T cells and gives them fresh, without freezing, at a fraction of what a commercial product costs.
Yechezkel Barenholz
Professor, Laboratory of Membrane and Liposome Research, Hebrew University-Hadassah Medical School
Liposome scienceNanomedicineDrug delivery
Invented the chemistry that made Doxil work, the first nanomedicine any regulator approved, which is still a standard treatment for relapsed ovarian cancer three decades later.
Yoram G. Weiss
Director General
Hospital managementAnaesthesiology and critical care
Director General of Hadassah Medical Center in Jerusalem since 2021.
Similar pages
- TreatmentNXC-201 CAR-T
Shares Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial (HBI0101), HBI0101 (NXC-201) multiple myeloma phase 1, BCMA, CAR-T cell therapy.
- PersonEphrat Levy-Lahad
Shares Hebrew University of Jerusalem, Shaare Zedek Medical Center, Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD).
- Key paperPopulation-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2
Shares Shaare Zedek Medical Center, Sheba Medical Center, Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD).
- IdeaPlan the second CAR-T target before the first one is lost
Shares BCMA, Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy.
- PersonRachel Michaelson-Cohen
Shares Shaare Zedek Medical Center, Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing.
- CompanyCellogen Therapeutics
Shares Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
- PersonEitan Friedman
Shares Sheba Medical Center, Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing.
- PersonZelig Eshhar
Shares Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.